APA (7th ed.) Citation

L, D., J, C., P, L., A, W., S, B., A, V. M., . . . N, D. L. (2026). GLP1-E2 therapy delays autoimmune diabetes in late-stage prediabetic NOD mice and potentiates low-dose anti-CD3 therapy for enhanced disease protection. Diabetologia, 69(8), 2307. https://doi.org/10.1007/s00125-026-06750-1

Chicago Style (17th ed.) Citation

L, Degroote, et al. "GLP1-E2 Therapy Delays Autoimmune Diabetes in Late-stage Prediabetic NOD Mice and Potentiates Low-dose Anti-CD3 Therapy for Enhanced Disease Protection." Diabetologia 69, no. 8 (2026): 2307. https://doi.org/10.1007/s00125-026-06750-1.

MLA (9th ed.) Citation

L, Degroote, et al. "GLP1-E2 Therapy Delays Autoimmune Diabetes in Late-stage Prediabetic NOD Mice and Potentiates Low-dose Anti-CD3 Therapy for Enhanced Disease Protection." Diabetologia, vol. 69, no. 8, 2026, p. 2307, https://doi.org/10.1007/s00125-026-06750-1.